News | June 21, 2021
Zydus and Bayer announce extension of their JV
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Subscribe To Our Newsletter & Stay Updated
